Drug Watch

Long-term safety data suggests that JAK inhibitors have a lower risk of cardiovascular and thromboembolic events than previously thought.

The drug, a JAK inhibitor, met all primary and secondary endpoints in a phase 3 trial for adolescent CHE.

The IL-36R antagonist has demonstrated its safety and efficacy for generalized pustular psoriasis in GEMINI-1 and GEMINI-2 studies.

QRX003 mimics the LEKTI protein to strengthen skin barriers and alleviate symptoms in patients with Netherton Syndrome.

Fast-acting therapies like remibrutinib bring new hope to patients with chronic urticaria who don’t respond to antihistamines.

The new dosing option offers convenience for those managing plaque psoriasis, PsA, and hidradenitis suppurativa.

Shanna Miranti, MPAS, PA-C, discusses the Umary hyaluronic acid tablets that were recalled in fall 2024.

Mitragotri said new innovations like ionic liquid-based delivery systems can offer better treatment for immunodermatological conditions.

The innovative technology is unlocking new possibilities in dermatology by improving the solubility and permeability of drugs for topical use.

Dermatology Times is reviewing some of the most anticipated PDUFA dates of the upcoming year.

Deucravacitinib achieved ACR20 response in patients with PsA at week 16, with a safety profile consistent with previous studies.

The company stated INF904 disrupts inflammatory pathways with over 90% effectiveness, based on Phase 1 data.

If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.

According to the company, comparative tests revealed PN-881 surpasses or matches the efficacy of current injectable IL-17 therapies.

The drug is the first FDA-approved treatment for moderate to severe HS that selectively inhibits both IL-17A and IL-17F.

Delgocitinib is indicated for adults with CHE who either do not respond to or cannot use topical corticosteroids.

Abeona's pz-cel has been granted a April 29, 2025, PDUFA date.

The target action review date has been pushed to March 12, 2025.

This represents the second approval of Zoryve outside the US.

Light delves into the science behind the new peer-reviewed data assessing benzene presence and formation in benzoyl peroxide products.

New peer-reviewed research published in the Journal of Investigative Dermatology examined 111 products at room temperature.

Key highlights of the presentations included data on delgocitinib for atopic hand eczema, and tralokinumab for head and neck atopic dermatitis.

Through collaboration with Nimbus Therapeutics and Schrodinger, zasocitinib’s AI-driven design maximizes its fit within the targeted enzyme.

The FDA has set a PDUFA target action date of May 22, 2025.

Bimzelx was also approved for non-radiographic axial spondyloarthritis and ankylosing spondylitis.